← all systems · see it in The System
Receptor-ligand binding
In biochemistry and pharmacology, receptors are proteins that receive and transduce signals that may be integrated into biological systems. In protein-ligand binding, the ligand is usually a molecule which produces a signal by binding to a site on a target protein.
Properties published scienceour proposal
Sourced fields, and our own readings.
| born at | with the first cells (rung 6); not dated in the sources read |
| born precision | not given |
| boundary | Inside: one ligand and one receptor's binding site from encounter to release, the receptor's conformational change and its coupling to an effector, and the regulation of the receptor's sensitivity; the measures the field uses (Kd, kon, koff, residence time, efficacy). Outside: the downstream signalling cascades, the cell's decisions, the body's pharmacokinetics (how the drug reaches the tissue) and the chemistry that makes the ligand. |
| nested level | A molecular event inside the receptor floor of a cell (the cell's L2) and inside the binding pocket of a protein; built from a ligand, a receptor protein's site and the water between them; embedded in membranes, clefts and cytoplasm; carries pharmacology and drug discovery. |
| scale | molecular |
Measures (23) published science
| Dissociation constant | Kd = koff/kon (the same Kd from fast-on fast-off or slow-on slow-off) M |
| Association rate constant (kon), basal | 10^5 to 10^6 per molar per second |
| Association rate constant (kon), electrostatically assisted | 10^8 to 10^9 per molar per second |
| Association rate ceiling used for drug-target encounter | 10^9 per molar per second |
| Residence time of a drug-target complex | tR = 1/koff s |
| Minimum residence time at a given affinity | at least 12 min at Kd 1 pM; at least 11.5 days at Kd 1 fM time |
| Tiotropium dissociation half-time (M3 receptor) | 462 (Kd 10 pM, koff 0.0015 per min) |
| Time to equilibrium | 97% of equilibrium after 5 half-times; about 10-fold faster at 90% than at 10% occupancy; tiotropium 3.5 h at 100 pM, 35 h at 0.3 pM |
| Occupancy giving a maximal response (spare receptors) | <1 % of receptors |
| Maximal binding free energy per heavy atom | about -1.5 kcal/mol per atom, flattening above about 15 heavy atoms |
| Enthalpy gained and entropy lost by one added hydrogen bond (HIV-1 protease inhibitor) | 3.9 kcal/mol each way, net affinity unchanged |
| Ligand-gated channel opening | rise within a microsecond; open for milliseconds |
| Haemoglobin quaternary transition | about 2 microseconds |
| Short-term desensitisation | minutes time |
| Downregulation | hours to days; beta2 receptor binding sites down 50-60% after prolonged agonist time |
| Members of the GPCR family (review) | approximately 800 genes |
| Members of the GPCR family (encyclopedia) | at least 810 members |
| Approved drugs acting at GPCRs | 475 drugs at 108 GPCRs, about 34% of FDA-approved drugs (abstract); 481 drugs at 107 GPCR targets (body text) |
| Receptor tyrosine kinases | 20 classes, 58 receptors |
| Clark's acetylcholine uptake estimate against later measurements | about 1000 times too high ratio |
| Rebinding factor used in simulations | 3 to 100 (kon x [Rtot]/k) dimensionless |
| Acetylcholine-binding sites on a nicotinic receptor | 2-5 sites |
| Rise of the GPCR response after agonist binding | within seconds; peaks within a few milliseconds to a few minutes depending on the receptor, then declines while the complex persists time |
Open contentions (7) open contention
Where sources or readings disagree. Both stay on the map.
- C-3902 Can a drug's grip on its receptor be measured separately from its power to switch the receptor on?
booked: The map keeps the competing readings; none is ruled.
the other reading: separable (Stephenson 1956; Ariens 1954); inextricably linked for agonists (Colquhoun 1998; Rang 2006) - C-3939 Did molecular receptors begin with proteins in cells, or earlier with RNA?
booked: The map keeps the competing readings; none is ruled.
the other reading: receptors begin with protein receptors in cells; RNA sensors before protein (riboswitches as relics; proposed) - C-3943 How many receptors of the largest drug-target family are there, and how many drugs act on them?
booked: The map keeps the competing readings; none is ruled.
the other reading: ~800 (Smith et al. 2018); >=810 (encyclopedia); 475 drugs / 108 GPCRs (Hauser abstract); 481 drugs / 107 GPCR targets (Hauser body) - C-3948 Why does a stronger chemical bond between a drug and its target so often fail to make it bind more tightly?
booked: The map keeps the competing readings; none is ruled.
the other reading: a general mechanism of biological homeostasis (as cited by Fox et al.); a common result of correlated experimental error (as cited by Fox et al.); real and physical, with several mechanisms (Fox et al. 2018) - C-3950 Does a molecule reshape its receptor on arrival, or pick out a shape the receptor already visits?
booked: The map keeps the competing readings; none is ruled.
the other reading: induced fit: the ligand changes the receptor's shape after binding (Koshland 1958-59; KNF sequential model), as quoted in Changeux & Edelstein 2011; conformational selection: the shapes pre-exist and the ligand selects one (MWC 1965; Changeux & Edelstein 2011); a continuum, tunable by the timescale of conformational transitions (Zhou 2010) - C-3952 What matters more for a drug: how tightly it binds, or how long it stays bound?
booked: The map keeps the competing readings; none is ruled.
the other reading: affinity (Kd) at equilibrium is what matters; slow koff (long residence time) drives duration of action; pharmacokinetics prevails for most drugs; rebinding and kon matter as much as koff - C-3994 Is a receptor a two-position switch, or does it have many active states?
booked: The map keeps the competing readings; none is ruled.
the other reading: two-state switch R/R* (del Castillo & Katz 1957; Rang 2006); graded activation and many active states (Rang's figure 3a; protean agonism); multistate allosteric microprocessors (Smith et al. 2018)
Cross-scale patterns seen here (17) our proposal
Shapes that recur when the same kind of problem is solved at different scales, and how each shows in Receptor-ligand binding. Each links to every other system that shows it.
- same role, different builds (structural)
One job, recognising a molecule and switching a function, done by unrelated builds: four protein receptor families (channel, seven-helix GPCR, enzyme-linked, nuclear) and RNA riboswitches, where 'the RNA alone is sufficient to carry out molecular recognition and gene control actions without the obli - same shape, opposite sign (structural)
One process, shifting the R to R* equilibrium by selective affinity, run in both directions: an agonist prefers R* and raises it, an inverse agonist prefers R and lowers it below basal ('a ligand that binds selectively to R will reduce the population of R*, whereas a conventional agonist, favouring - trade one property for another (structural)
Enthalpy bought with entropy: tighter contacts cost freedom, so 'additional hydrogen bonds between ligands and proteins often yield enthalpic and entropic contributions to binding that nearly cancel'; one inhibitor's added hydrogen bond gained 3.9 kcal/mol in enthalpy and paid the same in entropy. K - Umwelt: each system carves its own slice of one shared medium (structural)
Each receptor carves its slice of one chemical medium: 'each receptor will only bind with ligands of a particular structure', and receptors are sorted by what their ligands are (chemo-, mechano-, photo-, magneto-, gas-receptors). A cell's set of receptors is its chemical Umwelt. - who opens the door (structural)
The receptor is the port: a site the cell built and placed before the ligand arrives, waiting to be addressed; under conformational selection even the open shape exists unliganded and the ligand only selects it ('Spontaneous channel openings can be recorded in the absence of acetylcholine'). - causal ceiling (partial)
A limit set by the physics of encounter, not by instruments: with association capped near 10^9 per molar per second, 'the residence time of a 1 pM drug on the target must be at least 12 min whereas a 1 fM drug will have a residence time of at least 11.5 days'. - conservation law plus closure (partial)
The binding law (mass action, occupancy y = KA/(1+KA)) leaves response open; Clark closed it by assuming response equals occupancy, Stephenson by a stimulus S = ey and an unknown R = f(S), Black and Leff by a hyperbolic transducer function. Occupancy alone predicts no response until a second relatio - holding / entrainment (partial)
The cell sets the number of its receptors: downregulation removes them over hours to days by internalisation, lysosomal degradation and lower mRNA, upregulation adds them, to set sensitivity. Receptors are not replicating units, so this is control of a count, not of division. - namespace completeness (the map predicts its gaps) (partial)
Thornton's tree of steroid receptors predicts where missing ligands sit: 'ligands for some "orphan" receptors may be found among intermediates in the synthesis of ligands for phylogenetically related receptors'. A predicted slot, not yet shown filled in the abstract read. - templating (partial)
One architecture reused across about 800 receptors: 'All GPCRs share a common architecture' of seven helices; the ligand-gated channel's core 'is conserved in the superfamily from prokaryotes to eukaryotes'. Interchangeability of modules between receptors was not shown in the sources read. - The carry (partial)
The wait: equilibrium waits on the slowest step. A binding assay reaches 97% of equilibrium after five half-times set by koff (tiotropium: half-time 462 min, 35 h to equilibrate at 0.3 pM), and where a conformational change follows binding 'the reversal of which is rate limiting', the slowest proces - The Payment to Entropy (partial)
Specificity paid for in free energy: kinetic proofreading raises specificity 'above the level available from free energy differences' only 'when the reaction is strongly but nonspecifically driven, e.g., by phosphate hydrolysis' (the T-cell receptor's phosphorylation steps are this). Form: energy sp - the whole sets the local reference (partial)
What a ligand 'is' depends on the tissue and pathway: ligands 'can concurrently behave as agonist and antagonists at the same receptor, depending on effector pathways or tissue type', and bias can come from the system; with spare receptors a tissue's reserve sets an agonist's apparent potency. Each - lightning (surface)
At the nicotinic acetylcholine receptor the source studied, the channel's all-or-none opening releases the stored ion gradient as current within a microsecond; but the discharge is gated by binding and capped, which is the dark twin. - nested ladder (surface)
Receptor models as nested special cases: the reversible two-state model 'is perfectly compatible with the earlier formulations of Schild and Stephenson' when the unliganded equilibrium lies far toward R; the ternary complex adds the G protein to it. A ladder of models, not a ladder of implication in - seed (surface)
Gene duplication plus ligand exploitation elaborated 'an integrated system of increasing complexity' of hormone-receptor pairs; whether this unpacks combinatorics in the Seed sense is not shown. - symmetry breaking (name the cut) (surface)
In the MWC model transitions 'preserve its symmetry'; in the KNF induced-fit model a ligand on one subunit makes a mixed, asymmetric intermediate. Whether a cut is made at all is the contention itself.
Valence: what it trades, and with whom (16) published science
Each exchange with a neighbour, read from both sides: who gains, who pays, and what carries it.
- Hydrogen-bond network (water) via sys:hydrogen-bond-network · Receptor-ligand binding mixed
- Cell via sys:aqueous-solution · Receptor-ligand binding gain
- Protein via sys:aqueous-solution · Receptor-ligand binding gain
- Cell membrane via sys:cell-membrane · Receptor-ligand binding gain
- Aqueous solution via sys:aqueous-solution · Receptor-ligand binding gain
- Synapse via sys:aqueous-solution · Receptor-ligand binding gain
- Thermal energy (heat, temperature and heat flow) via sys:thermal-energy · Receptor-ligand binding mixed
- Human (Homo sapiens) via sys:aqueous-solution · Receptor-ligand binding gain
- Hydrophobic effect via sys:hydrogen-bond-network · Receptor-ligand binding gain
- Ligand-gated ion channel via sys:electrochemical-gradient · Receptor-ligand binding gain
- T cell receptor via sys:aqueous-solution · Receptor-ligand binding gain
- G protein-coupled receptor via sys:aqueous-solution · Receptor-ligand binding gain
- Dopamine via sys:aqueous-solution · Receptor-ligand binding gain
- Nuclear hormone receptors via sys:sequential-information · Receptor-ligand binding gain
- Heterotrimeric G protein via sys:cell-membrane · Receptor-ligand binding gain
- Beta-arrestin via sys:cell-membrane · Receptor-ligand binding loss
Partners and parts published science
Built from / builds (5)
Sits inside / holds (4)
expressed by (8)
- Recombination/Composition
- Interoperability/Transduction (Bridging)
- Internal Coordination/Regulation
- Sensing/Scanning
- Technique-Based Identification (a.k.a. Technique-Based Detection)
- Validation of Identity/Intention
- Redundancy & Diversity
- Quality Control & Error Correction
floor filled by (19)
- Hydrogen-bond network (water)
- Cell
- Protein
- Cell membrane
- Aqueous solution
- Synapse
- Human (Homo sapiens)
- Hydrophobic effect
- Ligand-gated ion channel
- Lysosome
- binding site
- Chemical equilibrium
- Allosteric (regulatory) sites
- Nuclear hormone receptors
- Ligand
- Kinase-linked and related receptors
- Heterotrimeric G protein
- Beta-arrestin
- GPCR kinase
represents (1)
Kinds (13)
- Lock and key (Fischer 1894)
- Two-state model (del Castillo-Katz and its reversible form)
- Covalent (irreversible) binding
- Orthosteric binding
- Allosteric binding
- Cooperative binding
- Bivalent ligand binding
- Induced fit (Koshland; KNF sequential model)
- Conformational selection (MWC concerted model)
- Occupancy theory (Clark)
- Rate theory (Paton)
- Operational model (Black and Leff)
- Ternary complex model
Notes published science
- Because two molecules can only meet so fast (about a billion encounters per molar per second at best), a drug that binds very tightly is forced to stay bound a long time: at a dissociation constant of 1 picomolar it must stay at least 12 minutes, and at 1 femtomolar at least 11.5 days (src:tonge-2018).
- The mineralocorticoid receptor could bind aldosterone long before animals made aldosterone: resurrecting the ancestral receptor showed the affinity was a by-product of binding older look-alike hormones, and two amino acid changes recreate today's specificity (src:bridgham-2006).
- Adding a hydrogen bond to an HIV protease inhibitor made binding 3.9 kcal/mol better in enthalpy and exactly that much worse in entropy, so the drug bound no more tightly than before; binding in water is 'stubborn' this way (src:fox-2018).
- The first estimate of how many receptors a tissue holds (Clark, from acetylcholine taken up by the frog heart) was about 1000 times too high, and the first true binding measurement in 1965 took a full year of work that a technician now does in under a day (src:rang-2006).
Layers
The ways it takes in its world, where they meet, and how it acts back, each from L1 (where it meets the world) up.
binding thermodynamics: water, heat and free energy at the site
- L1: Water around the empty site and around the ligand: hydrogen-bonded networks in the pocket and hydration shells on the ligand
- L2: Desolvation: water leaves the pocket and the ligand's surface; its enthalpy or entropy can drive binding or rejection; the classical released-water picture of the hydrophobic effect fits few real cases
- L3: The balance: dG = dH - TdS; tighter contacts cost freedom; enthalpy and entropy often compensate so affinity does not move; measured directly by isothermal titration calorimetry
- L4: Affinity as read out: the Kd; at most about 1.5 kcal/mol per heavy atom for the strongest binders, flattening past about 15 heavy atoms
receptor evolution: genes, duplication and new ligand pairs
- L1: Receptor genes: the first steroid receptor bound estrogen, then a progesterone receptor
- L2: Duplication: the full set of mammalian steroid receptors from two large-scale genome expansions
- L3: Latent affinity: the ancestral receptor already bound aldosterone as a by-product of binding older, similar ligands
- L4: Specificity tuned: two amino acid changes recreate today's specificity
- L5: New hormone-receptor pairs and an integrated system; orphan receptors whose ligands may sit among related synthesis intermediates
receptor-ligand binding as pharmacologists and biophysicists describe it: from ligand in solution to the response (reader's view)
- L1: The ligand free in the solution at the receptor: a transmitter, hormone, drug, toxin, ion or part of a microbe, at a concentration; binding itself drains the free pool (ligand depletion)
- L2: Encounter and association: diffusion to the site through a transient complex; kon about 10^5-10^6 per molar per second with no helping force, 10^8-10^9 with complementary charges; reversible by dissociation (koff); measured in real time by surface plasmon resonance
- L3: The bound complex: a site of complementary shape held by ionic bonds, hydrogen bonds, van der Waals forces and the hydrophobic effect, with water rearranged; affinity (Kd = koff/kon), occupancy and residence time (1/koff); saturable and finite. Three quantities on different footings: Kd an equilibrium constant, occupancy a concentration-dependent state, residence time a lifetime. For an agonist the Kd an experiment returns mixes binding with activation (contention C-3902); the number also depends on the method and conditions
- L4: The receptor's conformation: resting R and active R* (and desensitised states) in equilibrium; an agonist prefers R*, an antagonist neither, an inverse agonist R; efficacy; constitutive activity; allosteric coupling between sites (alpha); whether the ligand selects or induces the active shape is argued. Written here in two-state terms; whether there are two states or a landscape of many is argued (contention C-3994), as is whether the ligand selects or induces the active shape (C-3950)
- L5: Coupling to the effector: the channel opens (ionotropic), a G protein exchanges GDP for GTP (metabotropic), a kinase domain works (enzyme-linked), or the receptor carries itself to DNA (nuclear); relay, amplification or integration; with spare receptors a maximal response comes at low occupancy; the same recognise-and-switch architecture runs in RNA alone (riboswitches)
- L6: Regulation of the response: desensitisation over minutes (GRK phosphorylation, beta-arrestins), downregulation over hours to days (internalisation, degradation), up- and downregulation of receptor number; bias towards one pathway (ligand, receptor or system bias); allosteric modulators
- L7: What the cell and body do: a change in a cell's electrical activity, muscle contraction, secretion, gene expression; for a person, a hormone's effect, a sense, a drug's action or a poison's
the boardroom (shared floors)
- L3: The bound complex: affinity, occupancy and residence time; the site where ligand, competitors, water, heat and the tissue's geometry meet
- L4: The receptor's conformational equilibrium: R, R*, desensitised states; efficacy; allosteric coupling
- L5: Coupling to the effector: channel gating, G protein exchange, kinase activity, DNA binding; relay, amplification, integration
- L6: Regulation of sensitivity and pathway: desensitisation, downregulation, bias
- L7: The response of the cell and body
way in: Allosteric modulators (ligands at a second site)
- L1: A modulator in solution (e.g. a benzodiazepine; a pathway's end product for an enzyme)
- L2: Binding at a site distinct from the orthosteric one
- L3: The cooperativity factor alpha: raises or lowers the other ligand's affinity (and may change its efficacy)
way in: Covalent marks written on the receptor (GRK phosphorylation, ubiquitin)
- L1: Kinases in the cytoplasm (GPCR kinases)
- L2: The agonist-occupied receptor phosphorylated
- L3: Beta-arrestin recruited
- L4: G protein kept off the receptor
- L5: Ubiquitin marks for degradation; internalisation
way in: Heat (temperature)
- L1: Temperature of the solution and tissue
- L2: Temperature shifts Kd (van 't Hoff) and the off-rate
way in: Other ligands at the same site (antagonists, partial agonists, rival endogenous ligands)
- L1: A second ligand in the same solution
- L2: Mutually exclusive occupancy of one site: the agonist curve shifts in parallel (Schild's dose ratio)
way in: The ligand itself (agonist or endogenous ligand)
- L1: Free ligand at a concentration in the extracellular fluid, the cleft or the cytoplasm
- L2: Diffusion and encounter: the transient complex; the on-rate
way in: The membrane and tissue around the receptor (confinement, density, rebinding)
- L1: Receptors in membranes, often densely, facing clefts and walls
- L2: Hindered diffusion: effective on- and off-rates are both divided by (1 + kon[R]/k), so freed ligand rebinds before drifting away; receptors are not evenly spread (rafts, microdomains), which changes local density
way in: The receptor's own make and number (genes, mutations, expression)
- L1: The receptor's sequence; mutations
- L2: How many receptors the cell holds (up- and downregulation)
- L3: The unliganded R to R* balance: constitutive activity
way in: The transducer bound on the inside (G protein, arrestin)
- L1: G protein heterotrimers on the inner face (alpha with GDP, beta, gamma)
- L2: The G protein docks on the active receptor: the ternary complex
- L3: Coupling changes ligand affinity: an inverse agonist's affinity rises when the G protein is uncoupled
way in: Water (the solvent in the pocket and around the ligand)
- L1: The hydrogen-bond network of the solvent
- L2: Water in the pocket and on the ligand rearranged or displaced
way out: Enzyme activity (enzyme-linked receptors)
- L1: Proteins in the cytoplasm modified
- L5: An intracellular enzymatic domain, linked through one membrane helix
way out: G protein and second messengers (metabotropic)
- L1: Effector enzymes and second messengers in the cytoplasm
- L5: GDP exchanged for GTP; alpha leaves beta-gamma
way out: Gene expression (nuclear receptors)
- L1: Zinc fingers read DNA sequences
- L5: The liganded receptor moves to the nucleus
way out: Ion flow (ligand-gated channels)
- L1: Ions cross the membrane down their gradient
- L5: At the nicotinic acetylcholine receptor studied by the source: the channel opens all-or-none; open time varies with the agonist, the unitary conductance does not (a per-receptor finding)
way out: Receptor removal (internalisation and degradation)
- L1: Fewer receptors in the membrane
- L5: Receptors taken into vesicles
- L6: Downregulation over hours to days
way out: Release of the ligand back into the solution (dissociation, rebinding)
- L1: Back in the free pool
- L2: Freed ligand may rebind the same or nearby receptors first
- L3: The complex falls apart at koff; residence time 1/koff